New guselkumab data shows consistent rates of skin clearance in severe plaque psoriasis

Janssen, the pharma unit of healthcare giant Johnson & Johnson, has presented new data demonstrating consistent rates of skin clearance with guselkumab treatment among patients with moderate to severe plaque psoriasis.

The longer-term findings from VOYAGE 1 were presented at the 26th European Academy of Dermatology and Venereology Congress. They showed more than 80% of patients receiving guselkumab, including those initially treated with placebo or the anti-tumor necrosis factor (TNF)-alpha agent adalimumab, achieved at least a 90% improvement in the psoriasis area severity index, or near complete skin clearance, and an investigator’s global assessment score of cleared or minimal disease at week 100.